Youn Jae Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Youn Jae Lee has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Eun Uk Jung
Department of Internal Medicine, Inje University Pusan Paik Hospital, Inje University College of Medicine, Busan, Korea
3 shared publicationsSang Yong Seol
Department of Internal Medicine, Inje University Pusan Paik Hospital, Inje University College of Medicine, Busan, Korea
3 shared publicationsSung Jae Park
Department of Internal Medicine, Inje University Pusan Paik Hospital, Inje University College of Medicine, Busan, Korea
3 shared publicationsJi Hyun Kim
Department of Internal Medicine, Inje University Pusan Paik Hospital, Inje University College of Medicine, Busan, Korea
2 shared publicationsSang Heon Lee
Department of Internal Medicine, Inje University Pusan Paik Hospital, Inje University College of Medicine, Busan, Korea
2 shared publicationsByoung Jin Choi
Department of Internal Medicine, Inje University Pusan Paik Hospital, Inje University College of Medicine, Busan, Korea
1 shared publication
Latest Publications
- Open Access
- 1 January 2011
- Published by The Korean Association for the Study of the Liver in Clinical and Molecular Hepatology
- Vol. 17 (3) , 183-188
Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin
The reappearance rates of hepatitis C virus (HCV) RNA after a sustained virological response (SVR) have been reported to be 1-2%. We investigated the reappearance rate of HCV RNA after SVR in chronic hepatitis C (CHC) patients treated with pegylated interferon (PEG-IFN) and ribavirin. In total, 292 CHC patients who achieved an SVR after PEG-IFN and ribavirin treatment were included. They were treated with subcutaneous injections of either PEG-IFN-α 2a or 2b plus ribavirin orally. Liver function tests and qualitative HCV RNA assays were performed every 6 months during the follow-up period after an SVR. Among the 292 patients, 224 (genotype 1, 92; genotype non-1, 132) were followed up for more than 6 months after SVR. These 224 patients were aged 48.1±11.5 years (mean±SD), and 129 of them were male. The median follow-up duration was 18 months (range 6-60 months). The reappearance rate of HCV RNA during follow-up was 0%. Two patients who achieved an SVR developed hepatocellular carcinoma during the follow-up period. An SVR was maintained in all CHC patients treated with PEG-IFN plus ribavirin during a median follow-up of 18 months. However, a screening test for hepatocellular carcinoma is needed for patients with an SVR.
- 1 January 2011
- Published by The Korean Association for the Study of the Liver in Clinical and Molecular Hepatology
- Vol. 17 (3) , 183-188
Open AccessDurability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin
The reappearance rates of hepatitis C virus (HCV) RNA after a sustained virological response (SVR) have been reported to be 1-2%. We investigated the reappearance rate of HCV RNA after SVR in chronic hepatitis C (CHC) patients treated with pegylated interferon (PEG-IFN) and ribavirin. In total, 292 CHC patients who achieved an SVR after PEG-IFN and ribavirin treatment were included. They were treated with subcutaneous injections of either PEG-IFN-α 2a or 2b plus ribavirin orally. Liver function tests and qualitative HCV RNA assays were performed every 6 months during the follow-up period after an SVR. Among the 292 patients, 224 (genotype 1, 92; genotype non-1, 132) were followed up for more than 6 months after SVR. These 224 patients were aged 48.1±11.5 years (mean±SD), and 129 of them were male. The median follow-up duration was 18 months (range 6-60 months). The reappearance rate of HCV RNA during follow-up was 0%. Two patients who achieved an SVR developed hepatocellular carcinoma during the follow-up period. An SVR was maintained in all CHC patients treated with PEG-IFN plus ribavirin during a median follow-up of 18 months. However, a screening test for hepatocellular carcinoma is needed for patients with an SVR.
- Open Access
- 1 January 2010
- Published by The Korean Society of Gastroenterology in The Korean Journal of Gastroenterology
- Vol. 56 (1) , 33-38
24 Weeks Treatment with Pegylated Interferon Alfa Plus Ribavirin May Be Possible in Genotype 1 Chronic Hepatitis C Patients with Rapid Virological Response Who Have Low Pretreatment Viremia
Moon SS, et al. Korean J Gastroenterol. 2010 Jul;56(1):33-38. https://doi.org/10.4166/kjg.2010.56.1.33
- 1 January 2010
- Published by The Korean Society of Gastroenterology in The Korean Journal of Gastroenterology
- Vol. 56 (1) , 33-38
Open Access24 Weeks Treatment with Pegylated Interferon Alfa Plus Ribavirin May Be Possible in Genotype 1 Chronic Hepatitis C Patients with Rapid Virological Response Who Have Low Pretreatment Viremia
Moon SS, et al. Korean J Gastroenterol. 2010 Jul;56(1):33-38. https://doi.org/10.4166/kjg.2010.56.1.33
- Open Access
- 1 January 2008
- Published by The Korean Association for the Study of the Liver in The Korean Journal of Hepatology
- Vol. 14 (3) , 318-330
Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection
Kang MJ, et al. Korean J Hepatol. 2008 Sep;14(3):318-330. http://dx.doi.org/10.3350/kjhep.2008.14.3.318
- 1 January 2008
- Published by The Korean Association for the Study of the Liver in The Korean Journal of Hepatology
- Vol. 14 (3) , 318-330
Open AccessEffects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection
Kang MJ, et al. Korean J Hepatol. 2008 Sep;14(3):318-330. http://dx.doi.org/10.3350/kjhep.2008.14.3.318